Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENUINE: GX-188E and GX-I7 With or Without Pembrolizumab in HPV+ Head and Neck Cancer
NCT05286060Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, Cytokines & Interferons, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid, efineptakin alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Yonsei University. Started Mar 2022; status: active, not recruiting.
02
Drugs
tirvalimogene teraplasmidefineptakin alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05286060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286060.